Argent BiopharmaRGTLF Days Payable is 1,458.68 as of Dec. 2025, which is 89% above its 10-year median of 769.76. The stock has 8 warning signs investors should review. Among 923 Drug Manufacturers companies, Argent Biopharma ranks better than 98.16% on this metric.
The historical rank and industry rank for Argent Biopharma's Days Payable or its related term are showing as below:
RGTLF'
s Days Payable Range Over the Past 10 Years
Min: 232.65 Med: 769.76 Max: 6253.67
Current: 2836.98
During the past 13 years, Argent Biopharma's highest Days Payable was 6253.67. The lowest was 232.65. And the median was 769.76.
RGTLF's Days Payable is ranked better than 98.16% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs RGTLF: 2836.98
Argent Biopharma's Days Payable
declined
from Dec. 2024 (107,370.83) to Dec. 2025 (1,458.68).
It may suggest that Argent Biopharmaaccelerated paying its suppliers.
Argent Biopharma Days Payable Related Terms
Argent Biopharma Days Payable Historical Data
* Premium members only.
The historical data trend for Argent Biopharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Argent Biopharma Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Argent Biopharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Argent Biopharma's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Argent Biopharma (RGTLF) has a Days Payable of 1,458.68 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Argent Biopharma and its competitors. This is 89% above median its historical median of 769.76. Over the past decade, Argent Biopharma's Days Payable has ranged from 232.65 to 6,253.67. According to the industry distribution chart, Argent Biopharma ranks #17 out of 923 companies in the Drug Manufacturers industry, placing it in the top 1.8%.
Is Argent Biopharma's Days Payable too high?
Argent Biopharma's current Days Payable of 1,458.68 is 89% above median its 10-year median of 769.76. Over the past 10 years, this metric has ranged from a low of 232.65 to a high of 6,253.67. The Drug Manufacturers industry median Days Payable is 90.98. Argent Biopharma's value of 1,458.68 is 1503.3% above this industry median. Based on the distribution chart, Argent Biopharma ranks #17 out of 923 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Argent Biopharma's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Argent Biopharma ranks #17 out of 923 companies for Days Payable. This places Argent Biopharma in the top 2% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.98. Argent Biopharma's value of 1,458.68 is 1503.3% above this benchmark. Historically, Argent Biopharma's own Days Payable has ranged from 232.65 to 6,253.67 over the past decade. While the company's 10-year median is 769.76 vs. the industry median of 90.98, Argent Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Argent Biopharma's current Days Payable of 1,458.68 is 1503.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Argent Biopharma and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Argent Biopharma's current Days Payable is 1,458.68, which is 89% above median its own 10-year median of 769.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argent Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Argent Biopharma (RGTLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 25% above its estimated fair value. The current Days Payable is 1,458.68, which is 89% above median its 10-year median of 769.76 and 1503.3% above the Drug Manufacturers industry median of 90.98. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Argent Biopharma (RGTLF), the current Days Payable is 1,458.68 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGTLF has been successfully added to your 